Blood products company Haemonetics (NYSE:HAE). will be reporting results tomorrow before market open. Here’s what you need to know.
Haemonetics missed analysts’ revenue expectations by 1.3% last quarter, reporting revenues of $348.5 million, up 3.7% year on year. It was a slower quarter for the company, with organic revenue in line with analysts’ estimates.
Is Haemonetics a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Haemonetics’s revenue to decline 4.7% year on year to $327.3 million, a reversal from the 12.8% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.22 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Haemonetics has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 2.7% on average.
Looking at Haemonetics’s peers in the medical devices & supplies - specialty segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Inspire Medical Systems delivered year-on-year revenue growth of 22.7%, beating analysts’ expectations by 3.1%, and Integer Holdings reported revenues up 7.3%, topping estimates by 2%. Inspire Medical Systems traded up 1.8% following the results while Integer Holdings was also up 2.6%.
Read our full analysis of Inspire Medical Systems’s results here and Integer Holdings’s results here.
There has been positive sentiment among investors in the medical devices & supplies - specialty segment, with share prices up 5.9% on average over the last month. Haemonetics is up 13.5% during the same time and is heading into earnings with an average analyst price target of $96.30 (compared to the current share price of $63.58).
Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.